Abstract
The coronavirus 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with clinical manifestation cases are almost similar to those of common respiratory viral infections. This study determined the prevalence of SARS-CoV-2 and other acute respiratory viruses among patients with flu-like symptoms in Bukavu city Democratic republic of Congo. We screened 1352 individuals with flu-like illnesses seeking treatment in 10 health facilities. Nasopharyngeal swabs specimens were collected to detect SARS-CoV-2 using real-time reverse transcription-polymerase chain reaction (RT-PCR) and 10 common respiratory viruses were detected by multiplex reverse transcription polymerase chain reaction assay. Overall, 13.9% (188/1352) patients were confirmed positive for SARS-CoV-2. Influenza A 5.6% (56/1352), and Influenza B 0.9% (12/1352) were the most common respiratory viruses detected. Overall more than two cases of the other acute respiratory viruses were detected. Frequently observed symptoms associated with SARS-CoV-2 positivity were shivering (47.8%; OR= 1.8; CI: 0.88-1.35), cough (89.6%; OR=6.5, CI: 2.16-28.2), myalgia and dizziness (59.7%; OR=2.7; CI: 1.36-5.85). Moreover, coinfection was observed in 12 (11.5%) specimens. SARS-CoV-2, and Influenza A were the most co-occurring infections, accounting for 33.3% of all positive cases. This study demonstrates cases of COVID-19 infections co-occurring with other acute respiratory infections in Bukavu city during the ongoing outbreak of COVID-19. These data emphasize the need for routine testing of multiple viral pathogens for better prevention and treatment plans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by German Institute for Medical Mission (DIFAM) and by the UNIVERSITE EVANGELIQUE EN AFRIQUE (UEA) under the grant number 2020-610-CD
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
he study protocol was approved by the Interdisciplinary Center of Ethical Research (CIRE) of the Universite Evangelique en Afrique (UEA), Ref: CNES 001/DPSK/115PP/2021. Informed consent was obtained from all participants after being signed and the confidentiality of the data was ensured.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors